Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

Merck & Co. is strutting into the spotlight as a top contender among the most profitable cheap stocks, thanks to its robust ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients. The Australian cancer-treatment company said Monday the median rate for overall ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Immutep Ltd. announced strong median overall survival of 17.6 months in cohort B of the TACTI-003 (Keynote-PNC-34) phase IIb ...

It's also a great place to start if you're looking for dividend stocks, as nearly every stock on the Dow Jones Industrial ...